Regeneron Extends US Ebola Drug Deal
Regeneron has extended its agreement with a US health authority to supply its Ebola treatment through 2031 in a deal valued at approximately $270 million. The contract expansion comes amid a growing Ebola outbreak across several African countries.
Xurve View
Insights:
Xurve View
REGENERON PHARMACEUTICALS extended a supply agreement with the United States health authority worth $270 million on Monday morning. The expanded contract secures deliveries of the Inmazeb Ebola treatment through 2031. The deal comes as a severe outbreak spreads across Africa.
